medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2021, Número S3

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2021; 32 (S3)


Tratamiento con estatinas. La evidencia y el papel en la prevención primaria y secundaria

Morales-Villegas EC, Ray KK

Idioma: Inglés [English version]
Referencias bibliográficas: 13
Paginas: s212-216
Archivo PDF: 298.78 Kb.





REFERENCIAS (EN ESTE ARTÍCULO)

  1. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976; 29 (12): 1346-1348.

  2. Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis. 1980; 305: 259-266.

  3. Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med. 1981; 305 (9): 478-482.

  4. Brown MS, Goldstein JL. Lowering plasma cholesterol by raising LDL receptors. N Engl J Med. 1980; 305: 515-517.

  5. Goldstein JL, Brown MS. Lipoprotein receptors: genetic defense against atherosclerosis. Clin Res. 1982; 30: 417-426.

  6. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Nobel Lecture, 9 December 1985. Available in: https://www.nobelprize.org/prizes/medicine/1985/summary/

  7. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009; 29 (4): 431-438.

  8. Brown MS, Goldstein JL. A tribute to Akira Endo, discoverer of a "penicillin" for cholesterol. Atherosclerosis. 2004; 5: 13-16.

  9. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366 (9493): 1267-1278.

  10. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376 (9753): 1670-1681.

  11. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016; 374 (21): 2021-2031.

  12. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73 (24): 3168-3209.

  13. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41 (1): 111-188.




2020     |     www.medigraphic.com